Pharmascience Inc. issues voluntary recall of Ranitidine Tablets 75mg, 150mg and 300mg (all pack sizes and formats)

MONTREAL, Oct. 23, 2019 /CNW Telbec/ -APharmascience Inc.Ais voluntarily, on a precautionary basis, recalling Ranitidine Tablets 75mg, 150mg and 300 mg (all pack sizes and formats)Ato theAretail level (type 1 recall). On September 13, 2019, further to a Health Canada request regarding the potential presence of a nitrosamine impurity calledAN-nitrosodimethylamine (NDMA)Ain Ranitidine products, Pharmascience, along with other pharmaceutical manufacturers, ceased distribution of all Ranitidine products to wholesalers and retailers. AAPharmascience has since been working closely with Health Canada to determine the necessity of any additional actions. Pharmascience is committed to patient safety, therefore out of an abundance of caution, this voluntary type 1 recall action at the retail level is being undertaken.A NDMA is classified as a probable human carcinogen (a substance that could cause cancer) based on results from laboratory tests. NDMA is a known environmental contaminant and found in water and foods, including meats, dairy products, and vegetables.Consumers with questions regarding this recall can contact PharmascienceAMedical Information at 1-888-550-6060 or contact our team by email at
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«     2020    »